BACKGROUND: Similar to a subset of human patients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL. The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16. METHODS: Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye. The SP was assayed for the presence of hyperdiploid B-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo. In addition, enhanced apoptosis of chemoresistant NZB B-1 cells was examined by restoring miR-16 levels in nutlin-treated cells. RESULTS: Aging NZB mice develop a B-1 expansion and clonal development that evolves from MBL into CLL. An expansion in SP is also seen. Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo. Similar to B-1 cells, splenic NZB SP also has decreased miR-15a/16 when compared with C57Bl/6. Exogenous addition of miR-15a/16 to NZB B-1 cells resulted in increased sensitivity to nutlin. CONCLUSION: NZB serve as an excellent model for studying the development and progression of age-associated CLL. NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell. NZB B-1 chemoresistance may be related to reduced miR-15a/16 expression.
BACKGROUND: Similar to a subset of humanpatients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL. The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16. METHODS:Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye. The SP was assayed for the presence of hyperdiploidB-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo. In addition, enhanced apoptosis of chemoresistant NZBB-1 cells was examined by restoring miR-16 levels in nutlin-treated cells. RESULTS: Aging NZBmice develop a B-1 expansion and clonal development that evolves from MBL into CLL. An expansion in SP is also seen. Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo. Similar to B-1 cells, splenic NZB SP also has decreased miR-15a/16 when compared with C57Bl/6. Exogenous addition of miR-15a/16 to NZBB-1 cells resulted in increased sensitivity to nutlin. CONCLUSION:NZB serve as an excellent model for studying the development and progression of age-associated CLL. NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell. NZBB-1 chemoresistance may be related to reduced miR-15a/16 expression.
Authors: Youn K Shim; Dannie C Middleton; Neil E Caporaso; Jane M Rachel; Ola Landgren; Fatima Abbasi; Elizabeth S Raveche; Andy C Rawstron; Alberto Orfao; Gerald E Marti; Robert F Vogt Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Erica Salerno; Brian J Scaglione; Frederick D Coffman; Brian D Brown; Alessia Baccarini; Helen Fernandes; Gerald Marti; Elizabeth S Raveche Journal: Mol Cancer Ther Date: 2009-09-01 Impact factor: 6.261
Authors: Aaron E Foster; Fatma V Okur; Ettore Biagi; An Lu; Gianpietro Dotti; Eric Yvon; Barbara Savoldo; George Carrum; Michael Andreeff; Margaret A Goodell; Helen E Heslop; Malcolm K Brenner Journal: Mol Cancer Date: 2009-11-18 Impact factor: 27.401
Authors: M C Lanasa; S D Allgood; A D Volkheimer; J P Gockerman; J F Whitesides; B K Goodman; J O Moore; J B Weinberg; M C Levesque Journal: Leukemia Date: 2009-10-15 Impact factor: 11.528
Authors: S Kasar; E Salerno; Y Yuan; C Underbayev; D Vollenweider; M F Laurindo; H Fernandes; D Bonci; A Addario; F Mazzella; E Raveche Journal: Genes Immun Date: 2011-09-01 Impact factor: 2.676
Authors: S Kasar; C Underbayev; Y Yuan; M Hanlon; S Aly; H Khan; V Chang; M Batish; T Gavrilova; F Badiane; H Degheidy; G Marti; E Raveche Journal: Oncogene Date: 2013-09-02 Impact factor: 9.867